Company Information

  

Address: ONE MARINA PARK DR.  
City: BOSTON 
State: MA 
Zip Code: 02210 
Telephone: 617-466-3500 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. Our long-term vision is to build a multi-product kidney care company. Our marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is approved by the U.S. Food and Drug Administration, or FDA, for two indications. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. Additionally, in November 2017, the FDA approved Auryxia for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. With two FDA-approved indications, we will leverage our U.S. clinical and commercial infrastructure to make Auryxia available to millions of people with CKD and either iron deficiency anemia or elevated levels of serum phosphorus, which is referred to as hyperphosphatemia.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-0.79NAN/E
03/2018-1.40NAN/E
12/2017-1.43NAN/E
09/2017-1.50NAN/E
06/2017-1.71NAN/E
03/2017-1.34NAN/E
12/2016-1.52NAN/E
09/2016-1.56NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.17Total Liab/Total Assets1.09
Net Inc/Total Assets-1.03Total Liab/Inv Cap1.52
Net Inc/Inv Cap-1.44Total Liab/Comm Equity0.18
Pretax Inc/Net Sales-2.70Interest Coverage RatioNA
Net Inc/Net Sales-2.70Curr Debt/EquityNA
Cash Flow/Net Sales-1.54LTD/Equity-8.87
SG&A/NetSales1.64Total Debt/Equity-8.87
Asset Utilization   Liquidity  
Net Receivables Turnover9.06Quick Ratio2.49
Inventory Turnover1.21Current Ratio3.12
Inventory Day Sales0.00Net Rec/Curr Assets0.06
Net Sales/Work Cap0.63Inv/Curr Assets0.20
Net Sales/PP&E13.41  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 25.75 21.75 18.68 15.00
Cost of Goods Sold 8.42 10.28 8.28 6.69
Selling & Admin Exps 28.71 25.84 28.79 22.75
Operating Income -20.15 -22.75 -31.01 -23.72
Interest Exp NA NA NA NA
Pretax Income -21.52 -22.53 -30.72 -23.48
Other Income -1.37 0.22 0.29 0.24
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -21.52 -21.90 -30.43 -23.50

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 49.46 60.09 93.53 114.00
Receivables - Total 15.43 12.89 8.15 9.20
Inventories - Total 48.58 35.44 28.70 26.01
Total Current Assets 125.61 119.55 141.57 164.78
Net Property, Plant & Equipment 4.10 4.35 4.52 4.70
Total Assets 145.65 140.12 158.87 173.82
Liabilities        
Accounts Payable 54.65 44.52 45.03 36.54
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 55.05 44.92 45.42 36.92
Long-Term Debt 130.09 125.00 125.00 125.00
Total Liabilities 186.84 171.73 172.97 164.86
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.12 0.12 0.12 0.12
Retained Earnings -1,041.34 -1,019.82 -998.54 -968.11
Treasury Stock -0.36 -0.36 -0.36 -0.36
Total Stockholders' Equity -41.19 -31.61 -14.10 8.96
Total Liabilities and Stockholders' Equity 145.65 140.12 158.87 173.82

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -21.36 -33.43 -20.18 -29.16
Net Cash Provided by Investing Activities 0.03 -0.08 -0.08 -0.76
Net Cash Provided by Financing Activities 10.71 0.07 -0.22 3.38

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20137.00-46.73-0.58
12/201410.82-111.52-1.23
12/201513.68-123.14-1.19
12/201631.98-161.10-1.52
12/201760.64-163.44-1.43
Growth Rates71.56----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1814774,00461.44




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.